Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 18, Issue SUPPL. 2, 2007, Pages

  Besse, B ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; NAVELBINE; PEMETREXED; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; TUMOR BIOPSY; WHOLE BODY PET;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; RISK ASSESSMENT;

EID: 54349128928     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm025     Document Type: Article

References (13)

1. Greene FL, Balch CM, Fleming ID et al. (eds), AJCC (American Joint Committee on Cancer): Cancer Staging Handbook: TNM Classification of Malignant Tumors, 6th edition. New York, NY: Springer-Vedag 2002.
2. Silvestri GA, Tanoue LT, Margolis ML et al. The noninvasive staging of non-small cell lung cancer: The guidelines. Chest 2003; 123: 147S-156S.
3. Stewart LA, Pignon JP. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-909.
4. Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and Illa non-small-cell lung cancer. J Clin Oncol 2002; 20: 247-253.
5. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
6. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
7. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observabon in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial [erratum appears in Lancet Onool 2006; 7: 797]. Lancet Oncol 2006; 7: 719-727.
8. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patent data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352: 257-263.
9. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patents with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
10. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol 2004; 22: 1589-1597.
11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
12. Auperin A, Le Pechoux C, Pignon JP et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients. Ann Oncol 2006; 17: 473-483.
13. Furuse K, Fukuoka M, Kawahara M et al, Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine. and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.